Startups.Bio showcases an emerging biotech startup each week, selected by the analyst team at VentureRadar from the 10,000s of companies we track.
Vilya is a spin-out of the University of Washington Institute for Protein Design (IPD), with a platform to design membrane-permeable peptides with high structural accuracy, opening up a new class of medicines that combine the advantages of traditional small-molecule drugs and larger protein therapeutics. In a paper published in Cell in September 2022 titled “Accurate […]
Biotechnology is in the midst of a exciting era of innovation, with an ever-expanding toolbox of modalities and approaches spawning development of exciting new vaccines, medicines and therapies. VentureRadar’s Top 100 Emerging Biotech Start-ups report showcases 100 of the most exciting early-stage companies that are currently developing therapeutics for major health challenges globally. The companies […]
CorriXR Therapeutics is an oncology-focused biotherapeutics developing a novel gene editing platform technology. CorriXR has developed an innovative CRISPR/Cas molecule that disables the genome of a tumor cell but not the genome of a healthy cell thereby conferring target selectivity. It is uniquely directed towards knocking out genetic pathways to allow for a broad-based combinatorial […]